Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Database
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
    • ETFs Future-Forward 2021: An iShares Investing Symposium
    • Three Themes for 2021: An iShares & MSCI Investing Symposium
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. In Genomics, Tech Very Much Matters
Disruptive Technology Channel
Share

In Genomics, Tech Very Much Matters

Tom LydonApr 05, 2022
2022-04-05

Genomics has long been one of the more tech-centric corners of the healthcare space, and that remains the case today.

That’s a strong indication that disruptive technologies often intersect with and depend on one another. Among the related exchange traded funds, the ARK Genomic Revolution Multi-Sector Fund (ARKG ) nimbly taps into that trend.

Research confirms that technological evolution can have material benefits in the genomics space, including lower costs and, potentially, superior patient outcomes.

“According to our research, innovative neural-network-based algorithms can predict protein structures accurately in lab experiments and could turbocharge human therapies and agricultural breakthroughs,” says ARK Investment Management analyst Alexandra Urman.

As an actively managed fund, ARKG can be more responsive to equity-level technological advances in genomics. That’s meaningful on a number of fronts, including the potential to reduce costly pre- and early trial experimentation.

“Our research suggests that neural-network-based algorithms could reduce R&D costs, increase the value of clinical trial assets, and increase the probability of clinical trial phase transition. For example, enabling technologies could shorten the average time spent in pre-clinical experimentation,” adds Urman.

Obviously, the COVID-19 vaccines are exceptions, but the traditional pre-trial time for drugs and therapies can last up to several years. That’s a long time, and it takes capital for companies to stay afloat during that period. Said another way, if technology can effectively help biotech and genomics companies reduce pre-trial experimentation without adversely impacting patient outcomes, investors stand to benefit.

“Based on our model assumptions, that number drops to three years and, with neural-network-based algorithms, two years, as shown below. For the entire pipeline—from discovery to the registration of a therapeutic drug—technology could improve efficiency, reduce costs, and eliminate 3.5 years of research and development time,” notes Urman.

Interestingly, technological improvements as they pertain to the genomics industry may not broadly reduce research and development expenditures. However, tech advances could serve to boost the number of drugs entering trial pipelines. Over time, that could be advantageous in terms of addressing various unmet needs in the healthcare arena.

The $3.9 billion ARKG, which debuted in October 2014, holds 49 stocks. The fund is higher by 7.52% over the past month.

For more news, information, and strategy, visit our Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

Equity ETF Channel

Retirement Portfolio Redux: Is the 60%-40% Portfolio Dead?

Debbie CarlsonOct 22, 2020
2020-10-22

With the 10-year U.S. Treasury yield hovering below 1% and Federal Reserve Chairman Jerome Powell...

Equity ETF Channel

Portfolio Diversification Isn't Dead, It Was Just Sleeping

Debbie CarlsonOct 15, 2020
2020-10-15

Investors could be forgiven to think there was no reason to invest outside of the U.S. for the...

}
X